| Literature DB >> 33398242 |
Alieh Farshbaf1,2, Nooshin Mohtasham3, Reza Zare3, Farnaz Mohajertehran3,2, Seyed Abdolrahim Rezaee4.
Abstract
The coronavirus disease 2019 (COVID-19) emerges as current outbreak cause by Novel Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2). This infection affects respiratory system and provides uncontrolled systemic inflammatory response as cytokine storm. The main concern about SARS-CoV-2 pandemic is high viral pathogenicity with no specific drugs. MicroRNAs (miRs) as small non-coding RNAs (21-25 nt) regulate gene expression. The SARS-CoV-2 encoded-miRs affect human genes that involved in transcription, translation, apoptosis, immune response and inflammation. Also, they alter self-gene regulation and hijacked host miRs that provide protective environment to maintain its latency. On the other hand, Host miRs play critical role in viral gene expression to restrict infection. Over expression/inhibition of miRs might result in cell cycle irregularity, impaired immune response or cancer. In this manner, exact role of each miR should be specified. Mimic encoded-miRs like antagomirs showed successful result in phases of clinical trial prevent from negative effects of viral encoded-miRs. Products of mimic miRs are inexpensive corresponds to synthesis of primer; they are short and nanoscale in size. Although SARS-CoV-2 genome is undergoing evaluation, detection of exact molecular pathogenesis open up opportunities to for vaccine development. Salivaomics can evaluate SARS-CoV-2 genome, transcriptome, proteome and biomarkers like miRs in oral related and cancer disease. In this review, we studied the challenge and opportunities of miRs in therapeutic approach for SARS-CoV-2 infection, then overviewed the role of miRs in saliva droplet during SARS-CoV-2 infection and related cancer.Entities:
Keywords: COVID-19; SARS-CoV-2; Saliva biomarker; Therapeutic approach; microRNA
Year: 2020 PMID: 33398242 PMCID: PMC7772998 DOI: 10.1016/j.jobcr.2020.12.006
Source DB: PubMed Journal: J Oral Biol Craniofac Res ISSN: 2212-4268
List of selected SARS-CoV-2-encoded miRs target host gene.
| miR | Target gene | Up/down Regulation | Tissue | Effect | Ref. |
|---|---|---|---|---|---|
| nCoV-MD3 -3P | Down | Subvert the key role of | |||
| nCoV-MD241–3P | Down | Reduce expression of innate immune response genes like IFN I and result in respiratory infection | |||
| MD2-5p | Down | It interfered with pro-apoptotic enzyme activity and apoptosis process | |||
| MR147–3p | Down | As a checkpoint, it interfered to cell arrest when DNA damaged and need to repaired | |||
| MR147–3p | Up | Gut | Promote infection | ||
| MR385–3p | Up | Innate and adaptive immune cells | It boost Th1 differentiation and modulate regulatory T-cell activation and survival | ||
| MR359–5p | Up | All tissue except heart for | Cytoskeleton proteins are critical for viral replication and life cycle and help virus for surfing, internalization, | ||
| MR66–3p | Up | Spleen | TNF-α as a key cytokines provides “cytokine storm” during inflammation | ||
| MR147–3p | Up | Gut | As a biological membrane interfered with maintain of intestine equilibrium i.e., transporting ions, small molecules, and macromolecules and present gastrointestinal symptoms | ||
| MR198–3p | Up | Liver | It suppress IFN system responses in viral infections and manifest signs of liver damage | ||
| MR328–5p | Up | Lung, spleen, gut, liver | It reduced host antiviral effect following IFN-I suppression |
Human top ranked miRs expression in lung during COVID-19 progression.
| miR | Target gene | Up/down Regulation | Effect |
|---|---|---|---|
| miR-8066 | Up | -Activate NfKB to target pro-inflammatory cytokines and induce cytokine storm | |
| miR-5197–3p | Up | -Similar to miR-8066 | |
| miR-3611 | GABAergic synapse, morphine addiction and metabolism of xenobiotics by cytochrome P450 | Down | -Probably promote viral replication |
| miR-1468–5p | TGF-1 and MAPKs signalling | Up | -Cardiac fibrosis |
| miR-1307–3p | Up | -Promote inflammatory responses | |
| miR-3691–3p | TGF-signalling | Down | -Lung pathogenesis |
| miR-3934–3p | Down | -Affect glycosaminoglycan biosynthesis-heparan sulfate/heparin, other types of O-glycan biosynthesis and vitamin digestion-absorption mechanisms |
List of selected human miRs target SARS-CoV-2 genome and involve in cancer progression.
| miR | Effect | Ref. |
|---|---|---|
| miR-197–5p | Cardiovascular disease | |
| miR-338–3p | Liver, lung and gastric cancers | |
| miR-4778–3p | Cervical cancer radioresistance | |
| miR-6864–5p | Urothelial Carcinoma of the Bladder | |
| miR-5197–3p | Squamous cell lung carcinoma | |
| miR-15b-5p | Coronary Artery Disease | |
| miR-15a-5p | Kidney disease | |
| miR-548c-5p | Colorectal Cancer | |
| miR-548d-3p | Osteosarcoma | |
| miR-409–3p | Osteosarcoma | |
| miR-30b-5p | Esophageal squamous cell carcinoma | |
| miR-505–3p | Prostate cancer | |
| miR-520c-3p | Obesity/diabetes | |
| miR-30e-3p | Myocardial Injury | |
| miR-23c | Hepatocellular carcinoma | |
| miR-30d-5p | Non-small cell lung cancer | |
| miR-4684–3p | Colorectal cancer | |
| miR-518a-5p | Gastrointestinal tumors | |
| miR-5197 | Non-small cell lung cancer (NSCLC), HTLV-1, HIV-1, Ebola | |
| miR-3611 | Chronic obstructive pulmonary disease (COPD) | |
| miR-3934 | Colon cancer, lung cancer, NSCLC, rectal carcinoma mucosa | |
| miR-1307 | Severity of pulmonary hypertension in systemic scleroderma | |
| miR-3691–3p | Chronic obstructive pulmonary disease | |
| miR1468–5p | Glioma, hepatocellular carcinoma, Alzheimer’s disease |
Fig. 1Selected human miRs target SARS-CoV-2 genome that product structural protein. S protein: bind to host cell receptor, consist of two subunits; S1 define virus-host range and cellular tropism, S2 modulates virus-cell membrane fusion. E protein: form hydrophilic pores on host membranes in addition to viral recognition and pathogenesis. M protein: Three transmembrane proteins bind to nucleucapsid. N protein: Produce two domains that binding to viral RNA genome.